Halozyme Therapeutics Inc (HALO)

[biotechinvestor1]

It was a revenue beat but an earnings miss (vs. street consensus but whithin Halo’s own previous guidance.

I was hoping for a progress on infectious disease (COVID-19, flu). Other than the reference to the phase 1 HIV vaccine on one of the slides, I did not see/hear anything else.

I think the market laready anticipated this lukewarm earnings call. At after hours price of $45 per share, we have already had more than a 10% hair cut. 52 day moving average was also around $45.

I will be buying more.